학술논문
MM-498 Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory Multiple Myeloma: Switching From Doublet to Triplet
Document Type
Article
Author
Source
In: Clinical Lymphoma, Myeloma and Leukemia , Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting. (Clinical Lymphoma, Myeloma and Leukemia, October 2022, 22:S426-S427)
Subject
Language
English
ISSN
21522669
21522650
21522650